



1645/IFW
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Andreas Meinke *et al.*

Serial No.: 10/561,506


Filed: December 19, 2005

For: CHLAMYDIA PNEUMONIAE
ANTIGENS

Group Art Unit: 1645

Examiner: Ogunbiyi, Oluwatosin A.

Atty. Dkt. No.: SONN:085US

<p align="center">CERTIFICATE OF MAILING 37 C.F.R. 1.8</p> <p>I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:</p> <p>December 21, 2008 Date  Mark B. Wilson</p>

INFORMATION DISCLOSURE STATEMENT

MS AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:


In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/SONN:085US.

Applicants respectfully request that the listed documents be made of record in the present case.


Respectfully submitted,



Mark B. Wilson
Reg. No. 37,259
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201


Date: December 21, 2006

	Application Number:	10/561,506
	Filing Date:	December 19, 2005
	First Named Inventor:	Andreas Meinke
	Art Unit:	1645
	Examiner Name:	Ogunbiyi, Oluwatosin A.
Total Number of Pages in this Submission : _____		Attorney Docket Number: SONN:085US


ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input checked="" type="checkbox"/> Form PTO-1449 <input checked="" type="checkbox"/> References <u>B1-B14; C1-C36</u> <input type="checkbox"/> Foreign Search Report <input type="checkbox"/> Certified Copy of Priority Documents <input type="checkbox"/> Reply to Missing Parts/Requirements <input type="checkbox"/> Reply to Missing Parts/Requirements <input type="checkbox"/> Declaration(s) _____ <input type="checkbox"/> Copy of Notice of Missing Parts/Requirements	<input type="checkbox"/> Drawings(s) _____ <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation, Change of Correspondence Address <input type="checkbox"/> Statement under 37 CFR §3.73(b) <input type="checkbox"/> Designation of Patent Practitioners <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below) <input type="checkbox"/> Check in the amount of \$ <input checked="" type="checkbox"/> Authorized to be charged to deposit account if check insufficient or inadvertently omitted. Deposit account number: <u>50-1212/SONN:085US</u> <input type="checkbox"/> Sequence Statement <input type="checkbox"/> Paper Copy of Sequence Listing <input type="checkbox"/> Computer Readable Form (CRF) <input checked="" type="checkbox"/> Postcard <input type="checkbox"/> _____ <input type="checkbox"/> _____
Remarks:		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	Fulbright & Jaworski L.L.P.	Customer Number	32425
Signature			
Printed Name	Mark B. Wilson	Reg. No.	37,259
Date	December 21, 2006		

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: MS AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:			
Signature			
Typed or Printed Name	Mark B. Wilson	Date	December 21, 2006

Form PTO-1449 (modified)

Atty. Docket No.
SONN:085USSerial No.
10/561,506

List of Patents and Publications for Applicant's

Applicant
Andreas Meinke *et al.*

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:
December 19, 2005Group:
1645U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Page 1-3

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language
	B1	A 1924/2001	12/07/01	Austria	English
	B2	CA 2,045,869	12/29/91	Canada	English
	B3	EP 0464533	07/29/98	Europe	German (English Abstract/Claims)
	B4	WO 01/24822	04/12/01	WIPO	English
	B5	WO 01/54720	08/02/01	WIPO	English
	B6	WO 01/93903	12/31/01	WIPO	English
	B7	WO 01/93905	12/13/01	WIPO	English
	B8	WO 02/059148	08/01/02	WIPO	English
	B9	WO 02/095027	11/28/02	WIPO	English
	B10	WO 02/13857	02/21/02	WIPO	English
	B11	WO 02/32451	04/25/02	WIPO	English
	B12	WO 96/02555	02/01/96	WIPO	English
	B13	WO 97/30721	08/28/97	WIPO	German (English Abstract)
	B14	WO 99/38528	08/05/99	WIPO	German (English Abstract)

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Campbell <i>et al.</i> , "Isolation of a gene encoding a Chlamydia sp. strain TWAR protein that is recognized during infection of humans," <i>Infect. Immun.</i> , 57:71-75, 1989.

25716920.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. SONN:085US	Serial No. 10/561,506
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Andreas Meinke <i>et al.</i>	
		Filing Date: December 19, 2005	Group: 1645
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1-3</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C2	Cox <i>et al.</i> , "Deoxyribonucleic Acid Relatedness of Chlamydia sp. Strain TWAR to Chlamydia trachomatis and Chlamydia psittaci," <i>Int. J. Syst. Bacteriol.</i> , 38:265-268, 1988.
	C3	Dowell <i>et al.</i> , "Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada)," <i>Clin Infect Dis</i> , 33:492-503, 2001.
	C4	GenBank Accession Number: AB036071.
	C5	GenBank Accession Number: AB036072.
	C6	GenBank Accession Number: AB036073.
	C7	GenBank Accession Number: AB036074.
	C8	GenBank Accession Number: AB036075.
	C9	GenBank Accession Number: AB036076.
	C10	GenBank Accession Number: AB036077.
	C11	GenBank Accession Number: AB036078.
	C12	GenBank Accession Number: AB036079.
	C13	GenBank Accession Number: AB036080.
	C14	GenBank Accession Number: AB036081.
	C15	GenBank Accession Number: AB036082.
	C16	GenBank Accession Number: AB036083.
	C17	GenBank Accession Number: AB036084.
	C18	GenBank Accession Number: AB036085.
	C19	GenBank Accession Number: AB036086.
	C20	GenBank Accession Number: AB036087.
	C21	GenBank Accession Number: AB036088.
	C22	GenBank Accession Number: AB036089.

25716920.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. SONN:085US	Serial No. 10/561,506
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Andreas Meinke <i>et al.</i>	
		Filing Date: December 19, 2005	Group: 1645
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1-3</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C23	GenBank Accession Number: AE001363.
	C24	GenBank Accession Number: AE002161.
	C25	Genbank Accession Number: AP002545.
	C26	Genbank Accession Number: AP002546.
	C27	Genbank Accession Number: AP002548.
	C28	Hoe <i>et al.</i> , "Distribution of streptococcal inhibitor of complement variants in pharyngitis and invasive isolates in an epidemic of serotype M1 group A Streptococcus infection." <i>J. Infect. Dis.</i> , 183:633-639, 2001.
	C29	Hornef <i>et al.</i> , "Bacterial strategies for overcoming host innate and adaptive immune responses," <i>Nat. Immunol.</i> , 3:1033-1040, 2002.
	C30	Kalman <i>et al.</i> , "Comparative genomes of Chlamydia pneumoniae and C. trachomatis," <i>Nat. Genet.</i> , 21:385-389, 1999.
	C31	Murdin <i>et al.</i> , "Use of a Mouse Lung Challenge Model to Identify Antigens Protective against Chlamydia pneumoniae Lung Infection," <i>J. Infect. Dis.</i> , 181:S544-551, 2000.
	C32	Read <i>et al.</i> , "Genome sequence of Chlamydophila caviae (Chlamydia psittaci GPIC): examining the role of niche-specific genes in the evolution of the Chlamydiaceae," <i>Nucleic Acids Research</i> , 31:2134-2147, 2003.
	C33	Read <i>et al.</i> , "Genome sequences of Chlamydia trachomatis MoPn and Chlamydia pneumoniae AR39," <i>Nucleic Acids Research</i> , 28:1397-1406, 2000.
	C34	Shirai <i>et al.</i> , "Comparison of whole genome sequences of Chlamydia pneumoniae J138 from Japan and CWL029 from USA," <i>Nucleic Acids Research</i> , 28:2311-2314, 2000.
	C35	Tigr identifier: C. pneumoniae AR39, www.tigr.org/tigr-scripts/CMR2/CMRHomePage.spl .
	C36	Wizel <i>et al.</i> , "Multiple Chlamydia pneumoniae antigens prime CD8+ Tc1 responses that inhibit intracellular growth of this vacuolar pathogen," <i>J. Immunol.</i> , 169:2524-2535, 2002.

25716920.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.